High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.
Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH.
Hu B, et al. Among authors: qazilbash mh.
Leuk Lymphoma. 2019 Feb;60(2):442-452. doi: 10.1080/10428194.2018.1485908. Epub 2018 Jul 22.
Leuk Lymphoma. 2019.
PMID: 30032678